GREENVILLE, SC–(BUSINESS WIRE)–KIYATEC, the leader in clinically correlated and published functional precision oncology technology, today announced two key appointments as the company expands the use of 3D Predict™ clinical testing and expands its portfolio of pharmaceutical services for KIYA-PREDICT ™. KIYATEC is pleased to welcome Bruce Yeager as Vice President of Market Access and Reimbursement effective March 21, 2022, and Steven Holshouser, Ph.D., as Director of Business Development, effective March 21, 2022. of March 8, 2022.
Managing Director Matt Gevaert, Ph.D., said, “We are delighted to welcome Bruce and Steven to our growing team of experienced leaders in their respective fields. Bruce’s significant experience and effectiveness in securing and expanding Medicare and private payer reimbursement and coverage will support the commercialization of 3D Predict™ Glioma and Ovarian tests in 2022 and lay the foundation for reimbursement plans and coverage for our non-small cell lung, rare tumors, and breast cancer testing in the future. Steven’s track record in securing pharmaceutical service contracts will increase revenue for our growing portfolio of clients using KIYA-PREDICT™ therapeutic response and 3D cell culture technology applications in their drug development plans.
KIYATEC’s clinical and preclinical technological platforms, 3D PredictMT and KIYA-PREDICTMT, respectively, are leading the functional precision oncology space with published evidence of predictive response correlated to clinical outcomes. Recently, the company represented its 3D Predict™ Ovarian publications at the Society of Gynecologic Oncology (SGO) annual meeting on women’s cancer and announced the acceptance of six abstracts for presentation to the American Association for Cancer Research April 8-13, 2022 in New Orleans.
KIYATEC is a functional precision oncology company that measures live cancer cell response of individual patients through its innovative 3D cell culture technology platform. The company offers clinical tests for high-grade glioma and develops tests for ovarian, breast, non-small cell lung and rare tumors in its CLIA-certified laboratory. The company works with leading biopharmaceutical companies to unlock the response dynamics of their investigational drug candidates in the majority of solid tumor types. For more information, visit www.KIYATEC.com and join us on LinkedIn and Twitter.